Göm menyn

Publications for Hans Starkhammar

Co-author map based on Web of Sciences articles 2007-

Publications mentioned in social media 5 times*

Journal Articles

Jenny Drott, Hans Starkhammar, Karin Kjellgren and Carina Berterö
  The trajectory of neurotoxic side effects' impact on daily life: a qualitative study
  Supportive Care in Cancer, 2016, 24(8), 3455-3461.
   Fulltext  PDF  

P. A. Heedman, E. Canslatt, G. Henriks, Hans Starkhammar, Victoria Fomichov and Rune Sjödahl
  Variation at presentation among colon cancer patients with metastases: a population-based study
  Colorectal Disease, 2015, 17(5), 403-408.
 Web of Science® Times Cited: 1

Jenny Drott, Hans Starkhammar, Sussanne Börjeson and Carina Berterö
  Oxaliplatin induced neurotoxicity among patients with colorectal cancer: documentation in medical records - a pilot study
  Open Journal of Nursing, 2014, 4, 265-274.
   Fulltext  PDF  

Rune Sjödahl, Johan Rosell and Hans Starkhammar
  Causes of death after surgery for colon cancer-impact of other diseases, urgent admittance, and gender
  Scandinavian Journal of Gastroenterology, 2013, 48(10), 1160-1165.
 Web of Science® Times Cited: 1

Sussanne Börjeson, Hans Starkhammar, Mitra Unosson and Carina Berterö
  Common Symptoms and Distress Experienced Among Patients with Colorectal Cancer: A Qualitative part of Mixed Method Design
  Open Nursing Journal, 2012, 6(1), 100-107.
   Fulltext  PDF  

Kjell Magne Tveit, Tormod Guren, Per Pfeiffer, Halfdan Sorbye, Seppo Pyrhonen, Fridbjorn Sigurdsson, Elin Kure, Tone Fokstuen, Flemming Hansen, Eva Hofsli, Elke Birkemeyer, Anders Johnsson, Hans Starkhammar, Mette Karen Yilmaz, Nina Keldsen, Anne Berit Erdal and Thoralf Christoffersen
  Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
  Journal of Clinical Oncology, 2012, 30(15), 1755-1762.
 Web of Science® Times Cited: 286

Sussanne Börjeson, Hans Starkhammar and Carina Berterö
  Common symptoms experienced among patients with colorectal cancer, and barriers to reporting symptoms or distress; the staff perspective
  Austral-Asian Journal of Cancer, 2011, 10(1), 12-20.

Jasmine Loof, Johan Rosell, Charlotte Bratthall, Siv Doré, Hans Starkhammar, Hong Zhang and Xiao-Feng Sun
  Impact of PINCH expression on survival in colorectal cancer patients
  BMC CANCER, 2011, 11(103), .
   Fulltext  PDF  
 Web of Science® Times Cited: 5

B. Glimelius, H. Sorbye, L. Balteskard, P. Bystrom, P. Pfeiffer, K. Tveit, R. Heikkila, N. Keldsen, M. Albertsson, Hans Starkhammar, H. Garmo and A. Berglund
  A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
  Annals of Oncology, 2008, 19(5), 909-914.
 Web of Science® Times Cited: 31

C. Qvortrup, M. Yilmaz, D. Ogreid, A. Berglund, L. Balteskard, J. Ploen, T. Fokstuen, Hans Starkhammar, H. Sorbye, K. Tveit and P. Pfeiffer
  Chronomodulated capecitabine in combination with short-time oxaliplatin: A Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
  Annals of Oncology, 2008, 19(6), 1154-1159.
 Web of Science® Times Cited: 7

P Pfeiffer, H Sörbye, H Ehrsson, T Fokstuen, JP Mortensen, L Baltesgard, KM Tveit, D Ögreid, Hans Starkhammar, I Wallin, C Qvortrup and B Glimelius
  Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
  Annals of Oncology, 2006, 17(2), 252-258.
 Web of Science® Times Cited: 24

Bengt Glimelius, Olav Dahl, Björn Cedermark, Anders Jakobsen, Sören M Bentzen, Hans Starkhammar, Henrik Grönberg, Ragnar Hultborn, Maria Albertsson, Lars Påhlman and Kjell-Magne Tveit
  Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group
  Acta Oncologica, 2005, 44(8), 904-912.
 Web of Science® Times Cited: 78

Hans Starkhammar
  Aspects on priority settings in cancer treatment and care
  Acta Oncologica, 2005, 44(7), 667-672.

Lennart Hardell, Bert van Bavel, Gunilla Lindström, Michael Carlberg, Mikael Eriksson, Ann Charlotte Dreifaldt, Hans Wijkström, Hans Starkhammar, Arne Hallquist and Torgny Kolmer
  Concentrations of polychlorinated biphenyls in blood and the risk for testicular cancer
  International Journal of Andrology, 2004, 27(5), 282-290.
 Web of Science® Times Cited: 34

Vivi Bergman, Per Leanderson, Hans Starkhammar and Christer Tagesson
  Urinary excretion of 8-hydroxydeoxyguanosine and malondialdehyde after high dose radiochemotherapy preceding stem cell transplantation
  Free Radical Biology & Medicine, 2004, 36(3), 300-306.
 Web of Science® Times Cited: 24

Najme Wall and Hans Starkhammar
  Chemotherapy of soft tissue sarcoma: A clinical evaluation of treatment over ten years
  Acta Oncologica, 2003, 42(1), 55-61.
 Web of Science® Times Cited: 7

L Hardell, B van Bavel, G Lindstrom, M Carlberg, AC Dreifaldt, H Wijkstrom, Hans Starkhammar, M Eriksson, A Hallquist and T Kolmert
  Increased concentrations of polychlorinated biphenyls, hexachlorobenzene, and chlordanes in mothers of men with testicular cancer
  Journal of Environmental Health Perspectives, 2003, 111(7), 930-934.
 Web of Science® Times Cited: 116

Per-Anders Heedman and Hans Starkhammar
  Patterns of referral to a palliative care unit: An indicator of different attitudes toward the dying patient?
  Journal of Palliative Medicine, 2002, 5(1), 101-106.

Eva Åstradsson, Lena Granath, Per-Anders Heedman and Hans Starkhammar
  Cancer patients hospitalised for palliative reasons. Symptoms and needs presented at a University Hospital
  Supportive Care in Cancer, 2001, 9(2), 97-102.
 Web of Science® Times Cited: 24

Inger Sandén, Per Linell, Hans Starkhammar and Ullabeth Sätterlund Larsson
  Routinization and sensitivity: Interaction in oncological follow-up consultations
  Health, 2001, 5(2), 139-163.
 Web of Science® Times Cited: 7

Conference Articles

Jenny Drott, Hans Starkhammar, Sussanne Börjeson and Carina Berterö
  Identifying Oxaliplatin induced Neurotoxicity in Medical records - strengthening compassion
  18th ICCN (International Conference on Cancer Nursing), September 7-11, 2014, Panama City, Panama, 2014.

Jenny Drott, Carina Berterö, Sussanne Börjeson and Hans Starkhammar
  Neurotoxiska symtom vid adjuvant cytostatikabehandling hos patienter med kolorektalcancer
  Kirurgveckan i Linköping 2012,20-24 augusti, 2012.

Ph.D. Theses

Jenny Drott
  Neurotoxic side effects and impact on daily life in patients with colorectal cancer with adjuvant oxaliplatin-based chemotherapy

  Fulltext PDF

Sebastian Gnosa
  Astrocyte elevated gene-1 in relation to colorectal cancer development and radiotherapy response

  Fulltext PDF

Johan Lyth
  Clinical-epidemiological studies on cutaneous malignant melanoma: A register approach

  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.


Responsible for this page: Peter Berkesand
Last updated: 2017-02-21